Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Ohad Hammer
»
Articles
|
Ohad Hammer
163
Followers
4
Following
You are currently following Ohad Hammer
Stop Following
You are no longer following Ohad Hammer
Profile
Articles (63)
Instablog (
10
)
Comments (45)
Sort by:
Latest
|
Editors' Picks (6)
|
Most Commented
|
Most Popular
Incyte – Life After Debt (Part II)
on Oct 19, 2009
•
AZN
,
INCY
,
LLY
Incyte: Life After Debt (Part I)
on Oct 14, 2009
•
CLDX
,
IMGN
,
INCY
Micromet: The Clock Is Ticking
on Aug 24, 2009
•
BMY
,
IMGN
,
MITI
Incyte Presents Investors with Unique Dilemmas
on Aug 10, 2009
•
AZN
,
CEPH
,
INCY
Curagen: Positive Results at ASCO 2009
on Jul 07, 2009
•
CLDX
,
CRGN
,
IMGN
Alimta: The 'Winner' of ASCO 2009
on Jun 16, 2009
•
LLY
,
OSIP
,
RHHBY.PK
Top Biotech Picks for ASCO 2009 (Part II)
on May 27, 2009
•
ARQL
,
CRGN
,
EXEL
Top Biotech Picks for ASCO 2009 (Part I)
on May 27, 2009
•
ARQL
,
CRGN
,
EXEL
Micromet: More Reasons for Optimism
on May 11, 2009
•
ARQL
,
EXEL
,
IBB
Bright Prospects for Micromet (Part 2)
on Apr 24, 2009
•
IMGN
,
MEDX
,
MITI
Bright Prospects for Micromet (Part 1)
on Apr 24, 2009
•
BYERF.PK
,
INFI
,
MITI
Morphosys: A Biotech Rule Breaker (Part 2)
on Mar 30, 2009
•
AGN
,
ARRY
,
CEPH
Morphosys: A Biotech Rule Breaker (Part 1)
on Mar 30, 2009
•
MPHSF.PK
Good News for Roche and Excellent News For Immunogen
on Mar 20, 2009
•
DNA
,
IMGN
,
RHHBY.PK
Celgene Corporation: Take the Money and Run
on Mar 03, 2009
•
CELG
Spicing Up the Biotech Portfolio with Microcaps CuraGen and Curis
on Feb 23, 2009
•
CRGN
,
CRIS
,
CRXL
Rigel and Seattle Genetics: The Delicate Art of Expectation Management
on Feb 09, 2009
•
RIGL
,
SGEN
Rigel Still on Track, And Has Pfizer Found Its Next Blockbuster?
on Jan 08, 2009
•
PFE
,
RIGL
Immunogen and Exelixis Defy the Recession
on Dec 22, 2008
•
BMY
,
DNA
,
EXEL
Arqule’s Theater of the Absurd
on Nov 11, 2008
•
ARQL
Rigel Pharmaceuticals: Biotech Crisis or Opportunity?
on Nov 10, 2008
•
ABT
,
AGN
,
AMGN
Buying More Exelixis in the Post - GlaxoSmithKline Era
on Oct 28, 2008
•
EXEL
Why It's Time to Buy More Immunogen
on Oct 17, 2008
•
DNA
,
IMGN
Genentech's Decision Should Boost Immunogen Stock
on Oct 15, 2008
•
DNA
,
IMGN
'When There's Blood in the Streets', Buy Biotech Stocks
on Oct 10, 2008
•
ALNY
,
ALTH
,
AMGN
Licensing Deal Is Imminent for ArQule
on Oct 02, 2008
•
AMGN
,
ARQL
,
BMY
Exelixis: A Platform Company for Oncology
on Sep 03, 2008
•
EXEL
Micromet: Another Seal of Approval
on Aug 21, 2008
•
MITI
Genentech’s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans
on Aug 06, 2008
•
DNA
,
IMGN
,
SGEN
Immunogen's Wild Swings Due to Lack of Information at ASCO
on Jul 14, 2008
•
DNA
,
IMGN
,
SGEN
Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
on Jun 24, 2008
•
CELG
,
EXEL
,
GSK
Investing in miRNA: Beware the Hype, Follow the Money
on Jun 10, 2008
•
ALNY
,
ISIS
,
ROSG
1
2
Next Page
Articles by Ticker
ABT
,
AGN
,
ALNY
,
ALTH
,
AMGN
,
ARQL
,
ARRY
,
AZN
,
BBH
,
BMY
,
BYERF.PK
,
CEGE
,
CELG
,
CEPH
,
CLDX
,
CRGN
,
CRIS
,
CRXL
,
CVTX
,
DNA
,
EXEL
,
EZCH
,
GENZ
,
GILD
,
GSK
,
HRAY
,
IBB
,
IKAN
,
IMCL
,
IMGN
,
IMMU
,
INCY
,
INFI
,
ISIS
,
JNJ
,
KONG
,
LLY
,
LTON
,
MBRK
,
MEDX
,
MITI
,
MPHSF.PK
,
MRK
,
NVS
,
ORCT
,
OSIP
,
PARD
,
PFE
,
PPHM
,
RHHBY.PK
,
RIGL
,
ROSG
,
SGEN
,
SNTA
,
SNY
,
THLD
,
WYE
,
XBI
Latest Comments on Ohad Hammer's Articles
tarlabgab
on
Cell Genesys: The Promise of GVAX
: From what I understand lethal dose RT just prevent GVAX cell from...
more »
Penn Bioinvestor
on
Incyte Presents Investors with Unique Dilemmas
: INCY is one of the biotech stocks with great potential. Nice...
more »
Ohad Hammer
on
Curagen: Positive Results at ASCO 2009
: Sorry, cannot comment on that.
more »
bio boy
on
Curagen: Positive Results at ASCO 2009
: Ohad Hi What is your current opinion on GENZ and it's...
more »
Furd Turgeson
on
Alimta: The 'Winner' of ASCO 2009
: Allos has pralatrexate, which in my opinion will be the biggest...
more »
Ohad Hammer
on
Peregrine Pharmaceuticals May Be On To Something
: Let's wait for the data release at both conferences. The main...
more »
topicviewer
on
Peregrine Pharmaceuticals May Be On To Something
: From the evening wires: Just got picked for an oral...
more »
hpski
on
Top Biotech Picks for ASCO 2009 (Part II)
: This is a follow up to my previous post. Genmab will indeed be...
more »
hpski
on
Top Biotech Picks for ASCO 2009 (Part II)
: This is not an ASCO issue, however ASCO is overshadowing the...
more »
Ohad Hammer
on
Top Biotech Picks for ASCO 2009 (Part I)
: As I wrote, the list is incomplete. Besides, most of the important...
more »
Jonha's Pop
on
Top Biotech Picks for ASCO 2009 (Part I)
: Why is there no mention of ALTH ?
more »
on avastin
on
Micromet: More Reasons for Optimism
: my mistake. thanks for the clarification. On May 13 12:47 AM...
more »
Ohad Hammer
on
Micromet: More Reasons for Optimism
: I am not aware of a SGEN drug for ALL. They have drugs for all...
more »
on avastin
on
Micromet: More Reasons for Optimism
: is miti's ALL drug in the same patient population as SGEN's ALL...
more »
Ohad Hammer
on
Micromet: More Reasons for Optimism
: I think most of the negative sentiment can be attributed to the...
more »
Latest Comments on Ohad Hammer's Articles
Latest Comments on Ohad Hammer's Articles